Centron Bio – Neuroscience | Boston, M.A.
Centron Bio is redefining the treatment of neurological diseases through targeted genetic medicine delivery to the brain. They are developing a proprietary platform that enables safe, intravenous delivery of antisense oligonucleotides (ASOs) and other genetic therapeutics across the blood-brain barrier and into cells throughout the central nervous system (CNS). Their approach is unlocking scalable, non-invasive treatment options for patients suffering from Alzheimer’s, ALS and other neurodegenerative diseases that have long remained out of reach for traditional therapies.
Solutions
Blood-Brain Barrier Penetration: Centron Bio’s platform overcomes one of the greatest challenges in CNS drug development—efficiently and safely delivering genetic medicines systemically across the blood-brain barrier.
Intracellular Delivery: They not only reach the brain but also ensure that therapeutics reach the inside of neurons and glial cells, enabling true disease-modifying effects.
Enhanced Efficacy: Its delivery system amplifies ASO activity compared to standard formulations, improving potency and therapeutic potential.
Non-Invasive Administration: Unlike intrathecal approaches, their IV-delivered therapeutics allow for chronic, patient-friendly dosing and uniform brain distribution.
Strengths
- First-In-Class Platform
- Centron Bio is the first to demonstrate intravenous delivery of uncharged ASOs with confirmed intraneuronal uptake and functional outcomes in disease models.
- Strategic Pipeline
- With derisked ASO programs in Alzheimer’s and ALS, and in-licensing opportunities from leading pharma partners, they are accelerating toward clinical trials.
- World-Class Team
- Its founders and scientists come from globally respected institutions like Oxford University and The Florey Institute, backed by leading advisors and biotech veterans.
Meet the Co-founders
From left to right:
James Tran, Ph.D. – Chief Executive Officer
Rick Pierce – Chairman
Fazel Shabanpoor, Ph.D. – Chief Scientific Officer
Jiah Pearson-Leary, Ph.D. – Head of Corporate Strategy
Interactome Biotherapeutics – Biopharmaceuticals | Grand Rapids, M.I.
Interactome Biotherapeutics is revolutionizing drug delivery by leveraging human stem cell-derived nanotechnology to deliver medicines more efficiently. Utilizing this emerging therapeutic area, Interactome’s lead program in neuropathic pain, IB001, is advancing into clinical trials in 2026. Over the last five years, Interactome has generated internal and in-licensed intellectual property to circumvent challenges facing the commercial progress of the human body’s natural cellular communication system: Stem Cell Exosomes.
Solutions:
Interactome Biotherapeutics has developed an efficient chemistry, manufacturing and controls (CMC) process and platform capabilities that alleviate issues faced with lipid nanoparticles and adeno-associated virus technologies to target organ-specific diseases and deliver medicines in a safer, more efficient way.
The company’s bioprocess alleviates issues with current products, including reliability, consistency, potency, efficacy and non-immunogenicity to ensure success with FDA CMC filings. The team has resolved these major challenges and has in-licensed assets from the global leaders in the field to foster ongoing Big Pharma collaborations.
Strengths
- Interactome has generated significant in vitro and in vivo data, including eight studies in rodents and non-human primates, leveraging its Bioprocess and IB001.
- IB001 directly influences nerve dynamics and delivers anti-inflammatory, pro-growth, and immunomodulatory growth factors and non-coding RNA that induce positive target cell regulatory effects.
- IB001 creates value inflection for the organization as a lead asset and further validates expanded use of its CMC and Bioprocess platform.
- Interactome’s agile and iterative CMC and Bioprocess drastically reduces indication execution risk and provides significant overall cost reduction compared to AAV and LNP delivery technologies.
Meet the Co-founders
From left to right:
Adam Koster – Chief Executive Officer
Frederick Naftolin, MD, Ph.D. – Vice President
TMAB Therapeutics Inc. – Oncology | Houston, T.X.
TMAB Therapeutics, Inc., is an asset-centric oncology biotech developing first- and best-in-class antibody-based therapies that reprogram the solid tumor microenvironment, address a massive unmet medical need and improve patient survival and quality of life. TMAB is developing radioligand therapies and multi-specific antibody therapies, which were discovered at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and UTH Houston.
Solutions
TMAB Therapeutics is advancing a pipeline of antibody-based cancer therapies designed to kill tumor cells directly and remodel the tumor microenvironment. Its radiopharmaceutical platform leverages highly specific antibodies labeled with therapeutic isotopes to deliver DNA-damaging radiation directly to cancer cells, inducing cell death while sparing normal tissue.
TMAB’s multi-specific antibody candidates simultaneously engage immune checkpoints, restore vascular integrity, and activate macrophage and T cell responses, enabling deeper immune infiltration and sustained anti-tumor activity. Together, these complementary modalities position TMAB to address solid tumors through precision targeting, immune modulation, blood vessel normalization and direct cytotoxicity.
Strengths
- Proven Leadership Team
- TMAB is led by a seasoned and dynamic team with deep expertise in preclinical development, clinical development, and the commercial launch of over 10 approved oncology therapies, including Zejula™.
- Validated Targets
- Pipeline directed against clinically and commercially validated targets, supported by recent therapeutic approvals and significant industry transactions exceeding $1 billion in value.
- Robust Preclinical Validation
- Extensive in vivo efficacy, biodistribution and PK data support the potency, selectivity and translational potential of TMAB’s therapeutic pipeline.
Meet the Co-founders
From left to right:
Tinashe Chandauka, MD, Ph.D. – Chief Executive Officer
Josh Sharan, DO – Chief Operating Officer